TGFB1 and neoplasm: Quantitative analyses confirm an 11.1% increase in ADCC potency versus trastuzumab (14), a feature particularly consequential in gastric cancer’s immunosuppressive microenvironment—characterized by tumor-associated macrophage (TAM) infiltration and abundant immunosuppressive cytokines (e.g., IL-10, TGF-β).